Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Accumulated Expenses (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Accumulated Expenses for 12 consecutive years, with $14.7 million as the latest value for Q1 2026.

  • For Q1 2026, Accumulated Expenses fell 73.74% year-over-year to $14.7 million; the TTM value through Mar 2026 reached $14.7 million, down 73.74%, while the annual FY2025 figure was $24.4 million, 59.48% down from the prior year.
  • Accumulated Expenses hit $14.7 million in Q1 2026 for Syndax Pharmaceuticals, down from $24.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $71.1 million in Q2 2025 and bottomed at $3.1 million in Q1 2023.
  • Average Accumulated Expenses over 5 years is $26.4 million, with a median of $24.3 million recorded in 2022.
  • Year-over-year, Accumulated Expenses skyrocketed 994.2% in 2024 and then plummeted 73.74% in 2026.
  • Syndax Pharmaceuticals' Accumulated Expenses stood at $24.3 million in 2022, then surged by 64.18% to $39.9 million in 2023, then surged by 50.78% to $60.1 million in 2024, then tumbled by 59.48% to $24.4 million in 2025, then crashed by 39.64% to $14.7 million in 2026.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $14.7 million, $24.4 million, and $15.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.